Curated News
By: NewsRamp Editorial Staff
June 29, 2026

Gerresheimer Posts EUR 2.3B Revenue, Advances Transformation

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Gerresheimer's sale of Centor and debt refinancing will improve financial flexibility, potentially boosting shareholder value.
  • Gerresheimer published audited 2025 results with revenue up 16.6% to EUR 2.3 billion, adjusted EBITDA margin at 16.8%.
  • Gerresheimer strengthens compliance and transparency, ensuring ethical practices and safer drug delivery for patients worldwide.
  • Gerresheimer's drug delivery devices drove 5.2% organic growth in Plastics & Devices, offsetting decline in cosmetics packaging.

Impact - Why it Matters

This news matters because Gerresheimer's financial health and strategic moves directly affect the supply chain for critical pharmaceutical packaging and drug delivery systems. Investors and partners can expect improved financial stability as the company resolves accounting issues, sells non-core assets, and refinances debt. Patients ultimately benefit from continued innovation and reliable production of drug delivery devices, ensuring access to essential medications.

Summary

Gerresheimer, a global partner to the pharma, biotech, and cosmetics industries, has published its audited 2025 annual and consolidated financial statements, revealing revenue of EUR 2.3 billion and adjusted EBITDA of EUR 384 million. The results, released on NEWMEDIAWIRE, show organic revenue growth of +0.3% and an adjusted EBITDA margin of 16.8%. The company is moving forward with the sale of its U.S. subsidiary Centor and a comprehensive debt refinancing planned for this year, alongside the implementation of its transformation program (gto) for gradual margin improvement.

The Plastics & Devices division saw robust demand for drug delivery devices, driving a 5.2% organic revenue increase, while the Primary Packaging Glass division faced headwinds from subdued demand in cosmetics and oral liquids. Gerresheimer's CFO Wolf Lehmann emphasized that the publication of audited statements sends a positive signal to stakeholders, highlighting transparency and compliance. The company also addressed past accounting irregularities, including incorrect revenue recognition from bill and hold agreements, and has taken corrective measures such as revising its Code of Conduct and strengthening compliance.

Looking ahead, Gerresheimer expects 2026 revenues in the lower half of EUR 2.3 to 2.4 billion and an adjusted EBITDA margin between 17% and 18%. The sale of Centor is progressing well, and the planned refinancing will further improve the financial situation. The company's transformation program aims to drive margin improvement, with a focus on operational efficiency and growth in high-demand segments like drug delivery devices.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Gerresheimer Posts EUR 2.3B Revenue, Advances Transformation

blockchain registration record for this content.